# A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures

> **NCT03325439** · PHASE3 · TERMINATED · sponsor: **UCB Biopharma SRL** · enrollment: 9 (actual)

## Conditions studied

- Electroencephalographic Neonatal Seizures

## Interventions

- **DRUG:** Brivaracetam (BRV) intravenous (iv)
- **DRUG:** Brivaracetam (BRV) oral

## Key facts

- **NCT ID:** NCT03325439
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-07
- **Primary completion:** 2020-09-03
- **Final completion:** 2021-05-29
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Terminated (The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.)
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325439, "A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03325439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*